EVOME MEDICAL TECHNOLOGIES I (EVMT.CA) Stock Fundamental Analysis
Canada • TSX Venture Exchange • TSX-V:EVMT • CA30053H1055
0.005 CAD
0 (0%)
Last: May 6, 2025, 07:00 PM
EVMT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 16 industry peers in the Health Care Equipment & Supplies industry. EVMT has a bad profitability rating. Also its financial health evaluation is rather negative. EVMT is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- In the past year EVMT has reported negative net income.
- In the past year EVMT had a positive cash flow from operations.
- In the past 5 years EVMT always reported negative net income.
- In the past 5 years EVMT reported 4 times negative operating cash flow.
1.2 Ratios
- EVMT has a better Return On Assets (-66.99%) than 68.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -66.99% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-20.97%
ROA(5y)-17.84%
ROE(3y)-154.4%
ROE(5y)-98.04%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- EVMT's Gross Margin of 33.80% is on the low side compared to the rest of the industry. EVMT is outperformed by 62.50% of its industry peers.
- EVMT's Gross Margin has declined in the last couple of years.
- EVMT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 33.8% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-27.65%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- EVMT does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for EVMT has been increased compared to 1 year ago.
- The debt/assets ratio for EVMT is higher compared to a year ago.
2.2 Solvency
- EVMT has an Altman-Z score of -2.59. This is a bad value and indicates that EVMT is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of EVMT (-2.59) is better than 62.50% of its industry peers.
- The Debt to FCF ratio of EVMT is 3.25, which is a good value as it means it would take EVMT, 3.25 years of fcf income to pay off all of its debts.
- EVMT has a Debt to FCF ratio of 3.25. This is amongst the best in the industry. EVMT outperforms 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.25 | ||
| Altman-Z | -2.59 |
ROIC/WACCN/A
WACC8.49%
2.3 Liquidity
- A Current Ratio of 0.51 indicates that EVMT may have some problems paying its short term obligations.
- With a Current ratio value of 0.51, EVMT is not doing good in the industry: 62.50% of the companies in the same industry are doing better.
- A Quick Ratio of 0.24 indicates that EVMT may have some problems paying its short term obligations.
- Looking at the Quick ratio, with a value of 0.24, EVMT is doing worse than 68.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.51 | ||
| Quick Ratio | 0.24 |
3. Growth
3.1 Past
- EVMT shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.50%.
- EVMT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -39.95%.
- The Revenue has been growing by 73.88% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)4.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-140%
Revenue 1Y (TTM)-39.95%
Revenue growth 3Y438.98%
Revenue growth 5Y73.88%
Sales Q2Q%-49.05%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-400%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-0.65%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for EVMT. In the last year negative earnings were reported.
- Also next year EVMT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of EVMT indicates a rather cheap valuation: EVMT is cheaper than 100.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 0.06 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for EVMT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EVOME MEDICAL TECHNOLOGIES I / EVMT.CA FAQ
What is the fundamental rating for EVMT stock?
ChartMill assigns a fundamental rating of 2 / 10 to EVMT.CA.
What is the valuation status of EVOME MEDICAL TECHNOLOGIES I (EVMT.CA) stock?
ChartMill assigns a valuation rating of 2 / 10 to EVOME MEDICAL TECHNOLOGIES I (EVMT.CA). This can be considered as Overvalued.
How profitable is EVOME MEDICAL TECHNOLOGIES I (EVMT.CA) stock?
EVOME MEDICAL TECHNOLOGIES I (EVMT.CA) has a profitability rating of 1 / 10.
Can you provide the financial health for EVMT stock?
The financial health rating of EVOME MEDICAL TECHNOLOGIES I (EVMT.CA) is 2 / 10.